MicroRNA and non-small cell lung cancer

doi:10.3969/j.issn.1006-7795.2015.04.001

Abstract

Abstract:

Lung cancer has the highest world-wide cancer mortality. Current therapies for non-small cell lung cancer(NSCLC) patients are inefficient due to the lack of diagnostic and therapeutic markers. MicroRNAs(miRNAs) are a species of small non-coding single-stranded RNA of about 21 nucleotides that through partial sequence homology may interact with the 3'-untranslated region of target mRNA molecules. Recent evidence has shown that miRNA may function as tumor supressors or oncogenes, and alterations in miRNA expression may play a critical role in the initiation and progression of lung cancer. miRNAs are not only stable in paraffin embedded tissues and body fluids, but also in plasma and serum, which makes circulating miRNA a new kind of ideal biomarker that opens a new field for early molecular diagnosis of lung cancer, as well as for prediction of lung cancer survival and therapy.

Key words: microRNA, circulating miRNA, lung cancer, diagnosis, prognosis, therapy

CLC Number:

R734.2

Tan Xiaogang, Zhi Xiuyi. MicroRNA and non-small cell lung cancer[J]. Journal of Capital Medical University, 2015, 36(4): 519-524.

References

[1] Jemal A, Bray F, Center M M, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011,61(2):69-90.
[2] Yang L, Yang G, Zhou M, et al. Body mass index and mortality from lung cancer in smokers and nonsmokers: A nationally representative prospective study of 220,000 men in China[J]. Int J Cancer, 2009,125(9):2136-2143.
[3] Barad O, Meiri E, Avniel A, et al. MicroRNA expression detected by oligonucleotide microarrays: system establishment and expression profiling in human tissues[J]. Genome Res, 2004,14(12):2486-2494.
[4] Lai E C, Tomancak P, Williams R W, et al. Computational identification of Drosophila microRNA genes[J]. Genome Biol, 2003,4(7):R42.
[5] Lee I, Ajay S S, Yook J I, et al. New class of microRNA targets containing simultaneous 5'-UTR and 3'-UTR interaction sites[J]. Genome Res, 2009,19(7):1175-1183.
[6] Calin G A, Sevignani C, Dumitru C D, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers[J]. Proc Natl Acad Sci USA, 2004,101(9):2999-3004.
[7] Lewis B P, Burge C B, Bartel D P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets[J]. Cell, 2005,20(1):15-20.
[8] Zeng Y, Cai X, Cullen B R. Use of RNA polymerase II to transcribe artificial microRNAs[J]. Methods Enzymol, 2005,392:371-380.
[9] Barad O, Meiri E, Avniel A, et al. MicroRNA expression detected by oligonucleotide microarrays: system establishment and expression profiling in human tissues[J]. Genome Res, 2004,14:2486-2494.
[10] Grishok A, Pasquinelli A E, Conte D, et al. Genes and mechanisms related to RNA interference regulate expression of the small temporal RNAs that control C. elegans developmental timing[J]. Cell, 2001,106(1):23-34.
[11] Pall G S, Hanmilton A J. Improved nonhem blot method for enhanced detection of small RNA[J]. Nat Protoc, 2008,3(6):1077-1084.
[12] Jiang J, Lee E J, Gusev Y, et al. Real-time expression profiling of microRNA precursors in human cancer cell lines[J]. Nucleic Acids Res, 2005,33(17):5394-5403.
[13] Jamnikar Ciglenecki U, Grom J, Toplak I, et al. Real-time RT-PCR assay for rapid and specific detection of classical swine fever virals:comparison of SYBR Green and TaqMan MGB detection methods using novel MGB probes[J]. J Virol Methods, 2008,147(2):257-264.
[14] Hafner M, landgraf P, Ludwig J, et al. Identification of microRNAs and other small regulatory RNAs using cDNA library sequencing[J]. Methods, 2008,44(1):3-12.
[15] Rathjen T, Pais H, Sweetman D, et al. High throughput sequencing of microRNAs in chicken somites[J]. FEBS Lett, 2009,583(9):1422-1426.
[16] Morozova O, Marra M A. Applications of next-generation sequencing technologies in functional genomics[J]. Genomics, 2008,92(5):255-264.
[17] Gao W, Yu Y, Cao H, et al. Deregulated expression of miR-21, miR-143 and miR-18la in non-small lung cancer is related to clinicopathologic characteristics or patient prognosis[J]. Biomed Pharmacother, 2010,64(6):399-408.
[18] Yanaihara N, caplen N, Bowman E. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis[J]. Cancer Cell, 2006,9(3):189-198.
[19] Landi M T, Zhao Y, Rotunno M, et al. MicroRNA expression differentiates histology and predicts survival of lung cancer[J]. Clin Cancer Res, 2010,16(2):430-441.
[20] Lebanony D, Benjamin H, Gilad S, et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small cell lung carcinoma[J]. J Clin Oncol, 2009,27(12):2030-2037.
[21] Chansky K, Sculier J P, Crowley J J, et al. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer[J]. J Thorac Oncol, 2009,4(7):792-801.
[22] Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival[J]. Cancer Res, 2004,64(11):3753-3756.
[23] Tan X, Qin W, Zhang L, et al. A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis[J]. Clin Cancer Res, 2011,17(21):6802-6811.
[24] Bian H B, Pan X, Yang J S, et al. Upregualtion of microRNA-451 increase cisplatin sensitivity of non-small cell lung cancer cell line(A549)[J]. J Exp Clin Cancer Res, 2011,(30):20.
[25] Ceppi P, Mudduluru G, Kumarswamy R, et al. Loss of miR-200c expression induces an aggressive, Invasive, and chemoresistant phenotype in non-small cell lung cancer[J]. Mol Cancer Res, 2010,8(9):1207-1216.
[26] Weiss G J, Bemis L T, Nakajima E, et al. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines[J]. Ann Oncol, 2008,19(6):1053-1059.
[27] Seike M, Goto A, Okarno T, et al. miR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers[J]. Proc Natl Acad Sci USA, 2009,106(29):12085-12090.
[28] Cui S Y, Huang J Y, Chen Y T, et al. Let-7c governs the acquisition of chemo- or radioresistance and epithelial-to-mesenchymal transition phenotypes in docetaxel-resistant lung adenocarcinoma[J]. Mol Cancer Res, 2013,11(7):699-713.
[29] 张晓娟,董静,马红露,等.血清/血浆micreRNA检测方法探讨与建立[J].南京医科大学学报:自然科学版,2011,31:529-531.
[30] El-Hefnawy T, Raja S, Kelly L, et al. Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics[J]. Clin Chem, 2004,50(3):564-573.
[31] Zhang Y, Liu D, Chen X, et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration[J]. Mol Cell, 2010,39(1):133-144.
[32] Turchinovich A, Weiz L, Langheinz A, et al. Characterization of extracellular circulating microRNA[J]. Nucleic Acids Res, 2011,39(16):7223-7233.
[33] Sozzi G, Boeri M, Rossi M, et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study[J]. J Clin Oncol, 2014,32(8):768-773.
[34] Chen X, Hu Z, Wang W, et al. Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis[J]. Int J Cancer, 2012,130(7):1620-1628.
[35] Gilad S, Lithwick-Yanai G, Barshack I, et al. Classification of the four main types of lung cancer using a microRNA-based diagnostic assay[J]. J Mol Diagn, 2012,14(5):510-517.
[36] Van der Drift M A, Hol B E, Klaassen C H, et al. Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer[J]. Lung Cancer, 2010,68(2):283-287.
[37] Sirera R, Bremnes R M, Cabrera A, et al. Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer[J]. J Thorac Oncol, 2011,6(2):286-290.
[38] Hu Z, Chen X, Zhao Y, et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer[J]. J Clin Oncol, 2010,28(10):1721-1726.
[39] Silva J, Garcia V, Zaballos A, et al. Vesicle related mieroRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival[J]. Eur Respir J, 2011,37(3):617-623.
[40] Kaduthanam S, Gade S, Meister M, et al. Serum miR-142-3p is associated with early relapse in operable lung adenocarcinoma patients[J]. Lung Cancer, 2013,80(2):223-227.
[41] Wei J, Gao W, Zhu C J, et al. Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer[J]. Chin J Cancer, 2011,30(6):407-414.
[42] Cui E H, Li H J, Hua F, et al. Serum microRNA-125b as a diagnostic or prognostic biomarker for advanced NSCLC patients receiving cisplatin-based chemotherapy[J]. Acta Pharmacol Sin, 2013,34(2):309-313.
[43] Wang G K, Zhu J Q, Zhang J T, et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans[J]. Eur Heart J, 2010,31(6):659-666.
[44] Xing L, Todd N W, Yu L, et al. Early detection of squamous cell lung cancer in sputum by a panel of microRNA marker[J]. Mod Pathol, 2010,23(8):1157-1164.
[45] Yu L, Todd N W, Xing L, et al. Early detection of lung adenocarcinoma in sputum by a panel of microRNA marker[J]. Int Cancer, 2010,127(12):2870-2878.
[46] Han H S, Yun J, Lim S N, et al. Downregulation of cell-free miR-198 as a diagnostic biomarker for lung adenocarcinoma-associated malignant pleural effusion[J]. Int J Cancer, 2013,133(3):645-652.
[47] 方楚玲,郭琳琅.miRNA对肺癌化疗耐药调控研究进展[J].中华肿瘤防治杂志,2014,21(1):72-76.